<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="327">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747158</url>
  </required_header>
  <id_info>
    <org_study_id>PINV20-388</org_study_id>
    <nct_id>NCT04747158</nct_id>
  </id_info>
  <brief_title>COVID-19 Convalescent Plasma Therapy</brief_title>
  <acronym>TPCC</acronym>
  <official_title>COVID-19 Convalescent Plasma Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angelica Samudio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consejo Nacional de Ciencias y Tecnología, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Salud Pública y Bienestar Social, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de información y recursos para el desarrollo, Paraguay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional de Asunción</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label trial in which hospitalized patients with risk factors of severe&#xD;
      coronavirus disease 2019 [COVID-19] will be receive treatment with convalescent plasma (≤ 15&#xD;
      days from symptoms start).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Actual">January 10, 2021</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (30-day mortality)</measure>
    <time_frame>30 days</time_frame>
    <description>To evaluate the effectiveness of convalescent plasma therapy COVID-19, to decrease mortality in hospitalized patients with COVID-19 and who present some risk factor for clinical deterioration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>To describe the median length of hospital stay in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status</measure>
    <time_frame>0, 3, 7 and 14 days</time_frame>
    <description>To asses the changes of disease severity, according to the COVID-19 disease severity from the World Health Organization (WHO) Interim guidance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory marker: ferritin</measure>
    <time_frame>0, 7 and 14 days</time_frame>
    <description>To measure changes in ferritin (μg/L) at 0, 7 and 14 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory marker: D dimer</measure>
    <time_frame>0, 7 and 14 days</time_frame>
    <description>To measure changes in D dimer (mg/L) at 0, 7 and 14 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory marker: leukocytes</measure>
    <time_frame>0, 7 and 14 days</time_frame>
    <description>To measure leukocytes (/mm3) changes at 0, 7 and 14 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Antibody Titers</measure>
    <time_frame>0, 3 and 7 days</time_frame>
    <description>To measure immunoglobulin G (IgG) SARS-CoV 2 titles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfer to ICU</measure>
    <time_frame>30 days</time_frame>
    <description>To asses the frequency of patients admitted to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion related events</measure>
    <time_frame>4 hours</time_frame>
    <description>To asses the frequency of adverse events to convalescent plasma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVID-19 convalescent plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2</description>
    <arm_group_label>Convalescent plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 Years and older&#xD;
&#xD;
          -  Presence of risk factors of severe COVID 19 diagnosed by quantitative polymerase chain&#xD;
             reaction by reverse transcription (RT-qPCR)&#xD;
&#xD;
          -  Patients with no more than 15 days from the onset of symptoms&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severely ill patients admitted directly to the ICU.&#xD;
&#xD;
          -  Need for mechanical ventilation at the time of hospital admission, regardless of the&#xD;
             time of clinical evolution.&#xD;
&#xD;
          -  History of previous hypersensitivity to plasma transfusions.&#xD;
&#xD;
          -  History of immunoglobulin A (IgA) deficiency&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelica Jimenez de Samudio, MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facultad de Ciencias Médicas - Universidad Nacional de Asunción</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facultad de Ciencias Médicas - Universidad Nacional de Asunción</name>
      <address>
        <city>Asunción</city>
        <zip>111421</zip>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <link>
    <url>https://datos.conacyt.gov.py/proyectos/pdf/3449</url>
    <description>Open data' page of projects funded by CONACYT, Paraguay</description>
  </link>
  <reference>
    <citation>Yoon HA, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz RH 3rd, Wirchnianski AS, Paroder M, Fehn K, Serrano-Rahman L, Babb R, Sarwar UN, Haslwanter D, Laudermilch E, Florez C, Dieterle ME, Jangra RK, Fels JM, Tong K, Mariano MC, Vergnolle O, Georgiev GI, Herrera NG, Malonis RJ, Quiroz JA, Morano NC, Krause GJ, Sweeney JM, Cowman K, Allen S, Annam J, Applebaum A, Barboto D, Khokhar A, Lally BJ, Lee A, Lee M, Malaviya A, Sample R, Yang XA, Li Y, Ruiz R, Thota R, Barnhill J, Goldstein DY, Uehlinger J, Garforth SJ, Almo SC, Lai JR, Gil MR, Fox AS, Chandran K, Wang T, Daily JP, Pirofski LA. Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC. medRxiv. 2020 Dec 4. pii: 2020.12.02.20242909. doi: 10.1101/2020.12.02.20242909. Update in: JCI Insight. 2021 Jan 21;:.</citation>
    <PMID>33300012</PMID>
  </reference>
  <reference>
    <citation>Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, Shepherd JRA, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, van Helmond N, Butterfield BP, Sexton MA, Diaz Soto JC, Paneth NS, Verdun NC, Marks P, Casadevall A, Fairweather D, Carter RE, Wright RS. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020 Sep;95(9):1888-1897. doi: 10.1016/j.mayocp.2020.06.028. Epub 2020 Jul 19.</citation>
    <PMID>32861333</PMID>
  </reference>
  <reference>
    <citation>Clinical Management of COVID-19 - Interim guidance 27 May 2020. WHO reference number: WHO/2019-nCoV/clinical/2020.5</citation>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Nacional de Asunción</investigator_affiliation>
    <investigator_full_name>Angelica Samudio</investigator_full_name>
    <investigator_title>Principal Investigator, Director of Research Directorate, Professor of Pediatric Hematology</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2 infection</keyword>
  <keyword>Convalescent plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators will publish the results to compare data with other studies with COVID-19 convalescent plasma patients</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

